Literature DB >> 20435532

Current practice of hepatitis C treatment in Southern Italy.

Tommaso Stroffolini1, Aldo Spadaro, Vincenzo Guadagnino, Stefano Cosentino, Filippo Fatuzzo, Antonio Galdieri, Bruno Cacopardo, Ignazio Scalisi, Mauro Sapienza, Maurizio Russello, Gaetano Scifo, Pierluigi Frugiuele, Giuseppe Foti, Piero Luigi Almasio.   

Abstract

BACKGROUND: Only a small proportion of subjects referring to hospitals for hepatitis C virus (HCV) positivity receives antiviral therapy. AIM: To evaluate the rate of antiviral treatment and the causes for no treatment in HCV-RNA positive subjects seen in hospital settings. PATIENTS AND METHODS: A prospective study enrolling over a 6-month period (February-July 2009) all consecutive anti-HCV positive subjects initially referred (naïve patients) to 12 liver units in Southern Italy for HCV treatment.
RESULTS: Out of 608 subjects evaluated, 74 (12.2%) had no detectable HCV-RNA in the serum and thus were excluded. Of the remaining 534 HCV-RNA positive subjects, 357 (66.9%) were not treated for the following reasons: 49.9% were older than 65 years of age (75% of them >70 years), 14.3% had normal liver enzymes, 13.2% had compensated/decompensated cirrhosis, 10.4% refused treatment, 9.8% had ongoing substance or alcohol abuse. Multivariate analysis showed that females (O.R. 2.27; C.I. 95% 1.05-4.90) and subjects with low educational level (O.R. 4.38; C.I. 95% 1.27-15.11) were more likely to decline therapy.
CONCLUSIONS: The majority of patients with HCV infection does not receive antiviral treatment. The effectiveness of the current standard therapy for HCV infection is low despite its good efficacy.
Copyright © 2010 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20435532     DOI: 10.1016/j.dld.2010.03.020

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  3 in total

1.  Rheumatoid arthritis following PEG-interferon-alfa-2a plus ribavirin treatment for chronic hepatitis C: a case report and review of the literature.

Authors:  Bruno Cacopardo; Francesco Benanti; Marilia Rita Pinzone; Giuseppe Nunnari
Journal:  BMC Res Notes       Date:  2013-10-30

2.  Disease progression and health care resource consumption in patients affected by hepatitis C virus in real practice setting.

Authors:  Valentina Perrone; Diego Sangiorgi; Stefano Buda; Luca Degli Esposti
Journal:  Clinicoecon Outcomes Res       Date:  2016-10-14

Review 3.  Regional differences in treatment rates for patients with chronic hepatitis C infection: Systematic review and meta-analysis.

Authors:  Philip Vutien; Michelle Jin; Michael H Le; Pauline Nguyen; Sam Trinh; Jee-Fu Huang; Ming-Lung Yu; Wan-Long Chuang; Mindie H Nguyen
Journal:  PLoS One       Date:  2017-09-06       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.